Scancell Holdings plc (AIM:SCLP)
12.61
-0.25 (-1.91%)
Mar 6, 2026, 2:42 PM GMT
Scancell Holdings Employees
Scancell Holdings had 60 employees as of April 30, 2025. The number of employees decreased by 1 or -1.64% compared to the previous year.
Employees
60
Change (1Y)
-1
Growth (1Y)
-1.64%
Revenue / Employee
78.52K GBP
Profits / Employee
-91.85K GBP
Market Cap
133.35M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| 4basebio | 110 |
| Bioventix | 12 |
| Hemogenyx Pharmaceuticals | 16 |
| Avacta Group | 151 |
| Faron Pharmaceuticals Oy | 32 |
| PureTech Health | 56 |
| hVIVO | 301 |
| ImmuPharma | 6 |
Scancell Holdings News
- 5 weeks ago - Scancell Holdings plc (SCNLF) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma - GlobeNewsWire
- 3 months ago - Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma Transcript - Seeking Alpha
- 6 months ago - Scancell Holdings Plc (SCNLF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025 - GlobeNewsWire
- 8 months ago - Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ - GlobeNewsWire
- 1 year ago - PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma - Business Wire
- 2 years ago - PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free - Business Wire